Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2490MR)

This product GTTS-WQ2490MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&FOLH1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001014986.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 2346
UniProt ID P07766; Q04609
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2490MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5710MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ1820MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ644MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ10581MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ5813MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ12707MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ9293MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ13425MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRO132365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW